CR11562A - Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina - Google Patents

Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina

Info

Publication number
CR11562A
CR11562A CR11562A CR11562A CR11562A CR 11562 A CR11562 A CR 11562A CR 11562 A CR11562 A CR 11562A CR 11562 A CR11562 A CR 11562A CR 11562 A CR11562 A CR 11562A
Authority
CR
Costa Rica
Prior art keywords
antagonists
bis
piridilpiridonas
melanina
concentrating hormone
Prior art date
Application number
CR11562A
Other languages
English (en)
Inventor
Allen Scott
C Blackwell Ii William
Boros Eric
L Collins Jon
Hertzog Don
Liang Xi
Ray John
Michael Reister Steven
Samano Vicente
Sherrill Ron
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR11562A publication Critical patent/CR11562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion provee bis-piridilpiridonas novedosas que son antagonistas en el receptor 1 de la hormona concentradora de melanina (MCHR1), composiciones farmmaceuticas que las contienen, procedimientos para su preparacion , y su uso en terapia y para el tratamiento de la obesidad y/o diabetes.
CR11562A 2007-12-10 2010-07-09 Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina CR11562A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1252507P 2007-12-10 2007-12-10

Publications (1)

Publication Number Publication Date
CR11562A true CR11562A (es) 2010-09-23

Family

ID=40469812

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11562A CR11562A (es) 2007-12-10 2010-07-09 Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina

Country Status (15)

Country Link
US (1) US20110118261A1 (es)
EP (1) EP2231646A1 (es)
JP (1) JP2011506462A (es)
KR (1) KR20100117059A (es)
CN (1) CN102015684A (es)
AU (1) AU2008335187B2 (es)
CA (1) CA2708741A1 (es)
CO (1) CO6280470A2 (es)
CR (1) CR11562A (es)
EA (1) EA201070725A1 (es)
IL (1) IL206237A0 (es)
MA (1) MA31941B1 (es)
MX (1) MX2010006388A (es)
WO (1) WO2009076387A1 (es)
ZA (1) ZA201004010B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528869A (ja) * 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン類
JP2012528871A (ja) * 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン類
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2014028829A1 (en) 2012-08-16 2014-02-20 The Scripps Research Institute Novel kappa opioid ligands
CN103044394A (zh) * 2012-12-20 2013-04-17 北京理工大学 一种苯基氨基嘧啶衍生物及其制备方法和用途
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
JP7132237B2 (ja) * 2017-03-17 2022-09-06 ザ スクリプス リサーチ インスティテュート κオピオイド受容体アンタゴニストならびにそれに関連する産物および方法
EP3632900A4 (en) 2017-06-01 2021-03-24 Sumitomo Chemical Company Limited HETEROCYCLIC CONNECTION AND COMPOSITION WITH IT
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
CN109851542A (zh) * 2019-01-28 2019-06-07 爱斯特（成都）生物制药股份有限公司 一种(s)-n-甲基-n-(吡咯烷-3-基)乙酰胺二盐酸盐及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005085200A1 (ja) * 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体

Also Published As

Publication number Publication date
EP2231646A1 (en) 2010-09-29
MA31941B1 (fr) 2010-12-01
ZA201004010B (en) 2011-03-30
WO2009076387A1 (en) 2009-06-18
MX2010006388A (es) 2010-06-25
JP2011506462A (ja) 2011-03-03
AU2008335187B2 (en) 2012-03-29
CN102015684A (zh) 2011-04-13
KR20100117059A (ko) 2010-11-02
CA2708741A1 (en) 2009-06-18
AU2008335187A1 (en) 2009-06-18
EA201070725A1 (ru) 2011-02-28
CO6280470A2 (es) 2011-05-20
US20110118261A1 (en) 2011-05-19
IL206237A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
ECSP12011716A (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
PA8804901A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
CR9891A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2011000405A1 (es) Compuestos derivados de n-sulfonamido pirazolil policiclico; inhibidores de la liberacion y sintesis de peptidos beta-amiloides y y-secretasa; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades alzheimer, parkinson, sindrome de down, entre otras.
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
PA8567701A1 (es) Agonistas del receptor b3-adrenergico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)